L. Austin Doyle

4.7k total citations
71 papers, 2.2k citations indexed

About

L. Austin Doyle is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. Austin Doyle has authored 71 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 28 papers in Oncology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. Austin Doyle's work include PI3K/AKT/mTOR signaling in cancer (19 papers), Lung Cancer Treatments and Mutations (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). L. Austin Doyle is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (19 papers), Lung Cancer Treatments and Mutations (8 papers) and Colorectal Cancer Treatments and Studies (8 papers). L. Austin Doyle collaborates with scholars based in United States, Canada and Australia. L. Austin Doyle's co-authors include Martin J. Edelman, Leno Thomas, Joseph Aisner, Razelle Kurzrock, Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, John P. Perentesis and Chandra P. Belani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

L. Austin Doyle

69 papers receiving 2.2k citations

Peers

L. Austin Doyle

ONCOL

PRM

SURGE

Heike Richly Germany

Jean Charles Soria France

In‐Gu Do South Korea

Dana T. Aftab United States

Yan Qin China

Tak Yun South Korea

Susan C. Guba United States

G. Veerman Netherlands

Carol Peña France

Stephen Leong United States

Heike Richly Germany

L. Austin Doyle

1.1k ×1.0

1.2k ×1.3

ONCOL

736 ×0.9

PRM

380 ×1.0

181 ×0.6

SURGE

Citations per year, relative to L. Austin Doyle L. Austin Doyle (= 1×) peers Heike Richly

Countries citing papers authored by L. Austin Doyle

Since Specialization

Citations

This map shows the geographic impact of L. Austin Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Austin Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Austin Doyle more than expected).

Fields of papers citing papers by L. Austin Doyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Austin Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Austin Doyle. The network helps show where L. Austin Doyle may publish in the future.

Co-authorship network of co-authors of L. Austin Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of L. Austin Doyle. A scholar is included among the top collaborators of L. Austin Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Austin Doyle. L. Austin Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Elizabeth K., Carol Aghajanian, Robert L. Coleman, et al.. (2020). Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecologic Oncology Reports. 32. 100546–100546. 13 indexed citations

Webster, Jonathan, Raoul Tibes, Amanda L. Blackford, et al.. (2017). Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research. 61. 108–116. 44 indexed citations

González-Angulo, Ana M., Ian E. Krop, Argun Akçakanat, et al.. (2015). SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 107(3). 30 indexed citations

Khanh, T., Giovanna Speranza, Rachel Bishop, et al.. (2015). Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Investigational New Drugs. 33(3). 720–728. 105 indexed citations

Fouladi, Maryam, John P. Perentesis, Lars M. Wagner, et al.. (2014). A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 21(7). 1558–1565. 16 indexed citations

Konopleva, Marina, Roland B. Walter, Stefan Faderl, et al.. (2014). Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia. Clinical Cancer Research. 20(8). 2226–2235. 70 indexed citations

Frankel, Paul, Timothy W. Synold, Joanne Mortimer, et al.. (2014). Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. British Journal of Cancer. 111(12). 2268–2274. 14 indexed citations

Jasielec, Jagoda, Amy Kimball, Kenneth S. Cohen, et al.. (2014). Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV).. Journal of Clinical Oncology. 32(15_suppl). 8567–8567. 2 indexed citations

Naing, Aung, Patricia LoRusso, Siqing Fu, et al.. (2013). Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. British Journal of Cancer. 108(4). 826–830. 99 indexed citations

10.

Naing, Aung, Patricia LoRusso, Siqing Fu, et al.. (2012). Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. Clinical Cancer Research. 18(9). 2625–2631. 163 indexed citations

11.

Prado, Carla M., Tanios Bekaii‐Saab, L. Austin Doyle, et al.. (2012). Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. British Journal of Cancer. 106(10). 1583–1586. 90 indexed citations

12.

Jain, Nitin, Emily Curran, Neil M. Iyengar, et al.. (2012). Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).. Journal of Clinical Oncology. 30(15_suppl). 6582–6582. 6 indexed citations

13.

Philipp, Mario T., L. Austin Doyle, Dale S. Martin, et al.. (2011). A rhesus macaque model ofStreptococcus pneumoniaecarriage. Journal of Medical Primatology. 41(1). 60–66. 5 indexed citations

14.

Ott, Patrick A., Anne Hamilton, Amanda C. Jones, et al.. (2010). A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma. PLoS ONE. 5(1). e8714–e8714. 7 indexed citations

15.

Krasna, Mark J., Ziv Gamliel, W. Burrows, et al.. (2009). Pneumonectomy for Lung Cancer After Preoperative Concurrent Chemotherapy and High-Dose Radiation. The Annals of Thoracic Surgery. 89(1). 200–206. 36 indexed citations

16.

Karp, Judith E., Amanda L. Blackford, B. Douglas Smith, et al.. (2009). Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia Research. 34(7). 877–882. 54 indexed citations

17.

Safran, Howard, Mohan Suntharalingam, Thomas Ng, et al.. (2008). Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity. International Journal of Radiation Oncology*Biology*Physics. 70(2). 391–395. 83 indexed citations

18.

Edelman, Martin J., Mohan Suntharalingam, W. Burrows, et al.. (2008). Phase I/II Trial of Hyperfractionated Radiation and Chemotherapy Followed by Surgery in Stage III Lung Cancer. The Annals of Thoracic Surgery. 86(3). 903–910. 33 indexed citations

19.

Thomas, Leno, L. Austin Doyle, & Martin J. Edelman. (2005). Lung Cancer in Women. CHEST Journal. 128(1). 370–381. 137 indexed citations

20.

Belani, Chandra P., L. Austin Doyle, & Joseph Aisner. (1994). Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemotherapy and Pharmacology. 34(S1). S118–S126. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact